Drug intelligence / Profile preview

CANN001

Development stage: Unknown
Lead developer: Cannenta
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration: Topical

Overview

CANN001 is an investigational topical hydrogel wound dressing containing 0.3% 2-deoxy-D-ribose (2dDR), a small ribose-derived sugar. Developed by Cannenta in collaboration with the University of Western Australia, CANN001 is designed to promote wound healing by stimulating angiogenesis (the formation of new blood vessels) and upregulating the local expression of vascular endothelial growth factor (VEGF). It is being evaluated in a Phase 1 clinical trial for the treatment of diabetic foot ulcers (DFUs).

Other names: 2-deoxy-D-ribose hydrogel2-deoxy-D-ribose hydrogel dressing2dDR hydrogel

Targets

VEGFA (Vascular endothelial growth factor A)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on CANN001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CANN001.

Explore the full profile